In this article, published in Genetic Engineering and Biotechnology News, Matthew Majewski discusses three alternative reimbursement models to address the pricing challenges payers and manufacturers face to provide patient access to high-cost curative therapies.
To read the full article, click here.
ESMO 2025 Review: Bring me the horizon
From these sessions, CRA’s Aaron Everitt highlighted that while there are still relevant data releases and findings on existing immune checkpoint inhibitors,...